Neurospine.
2025 Mar;22(1):78-80. 10.14245/ns.2550298.149.
A Commentary on “Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes”
- Affiliations
-
- 1Department of Neurosurgery, Kotobuki Social Medical Corporation, Tominaga Hospital, Osaka, Japan
- KMID: 2566044
- DOI: http://doi.org/10.14245/ns.2550298.149
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes
- Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
- Denosumab (RANKL Inhibitor): A Potent Anti-Resorptive Agent
- Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
- Romosozumab: A Novel Agent in the Management of Osteoporosis
